| (Values in U.S. Thousands) | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | -100.00% |
| Net Income | -2,160 | -1,200 | -2,600 | -4,370 | -1,720 |
| Net Income Growth | -80.00% | +53.85% | +40.50% | -154.07% | +57.84% |
Nemaura Medical Inc
(NMRD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nemaura Medical Inc. is a medical technology company. It engages in developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R), BEAT(TM) diabetes, and proBEAT(TM). SugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor. Nemaura Medical Inc. is based in New York, United States.
Fiscal Year End Date: 03/31